目的 探討注射用胸腺肽α₁聯(lián)合注射用替加環(huán)素治療多重耐藥鮑曼不動(dòng)桿菌肺炎的臨床療效。方法 選取2015年9月—2016年9月在漯河市中心醫(yī)院呼吸內(nèi)科接受治療的多重耐藥鮑曼不動(dòng)桿菌肺炎患者84例，根據(jù)治療方案的差別分為對(duì)照組和治療組，每組各42例。對(duì)照組靜脈滴注注射用替加環(huán)素，首劑100 mg，加入到0.9%氯化鈉溶液100 mL中，然后50 mg，1次/12 h。治療組在對(duì)照組基礎(chǔ)上皮下注射注射用胸腺肽α₁，1.6 mL加入到0.9%氯化鈉溶液1 mL中，1次/d，1周后改為2次/周。兩組患者均連續(xù)治療14 d。觀察兩組的臨床療效，比較兩組的臨床癥狀消失時(shí)間和血清學(xué)指標(biāo)。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為80.95%、97.62%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，治療組體溫恢復(fù)正常時(shí)間、咳嗽消失時(shí)間和肺部啰音消失時(shí)間明顯短于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組血清堿性成纖維細(xì)胞生長(zhǎng)因子（bFGF）、降鈣素原（PCT）和髓系細(xì)胞可溶性觸發(fā)受體1（sTREM-1）水平均明顯降低，而白細(xì)胞介素-10（IL-10）水平均明顯升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。結(jié)論 注射用胸腺肽α₁聯(lián)合注射用替加環(huán)素治療多重耐藥鮑曼不動(dòng)桿菌肺炎具有較好的臨床療效，可改善臨床癥狀，調(diào)節(jié)血清學(xué)指標(biāo)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Thymalfasin for injection combined with Tigecycline for injection in treatment of multidrug resistant acinetobacter baumannii pneumonia. Methods Patients (84 cases) with multidrug resistant acinetobacter baumannii pneumonia in Department of Respiratory Medicine of Luohe Central Hospital from September 2015 to September 2016 were enrolled in this study. According to the difference treatment plan, patients were divided into control and treatment groups, and each group had 42 cases. Patients in the control group were iv administered with Tigecycline for injection, first dosage 100 mg added into normal saline 100 mL, then dose adjustment to 50 mg, once every 12 h. Patients in the treatment group were subcutaneous injection administered with Thymalfasin for injection on the basis of the control group, 1.6 mL added into normal saline 1 mL, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and clinical symptom disappearance time and serological indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.95% and 97.62%, respectively, and there was difference between two groups (P < 0.05). After treatment, body temperature recovery time, cough disappearance time, and lung rales disappearance time in the treatment group were shorter than those in the control group, and there was difference between two groups (P < 0.05). After treatment, the levels of bFGF, PCT, and sTREM-1 in two groups were significantly decreased, but the levels of IL-10 in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Thymalfasin for injection combined with Tigecycline for injection has clinical curative effect in treatment of multidrug resistant acinetobacter baumannii pneumonia, can improve clinical symptoms, and regulate serological index, which has a certain clinical application value.